HWP
HQL

Highline Wealth Partners’s abrdn Life Sciences Investors HQL Stock Holding History

Highline Wealth Partners’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-175
Closed -$2.85K – 1452
2026
Q1 		$2.85K Buy
175
+25
+17% +$418 ﹤0.01% 931
2025
Q4 		$2.52K Sell
150
-850
-85% -$14.3K ﹤0.01% 805
2025
Q3 		$15.5K Buy
+1,000
New +$13.7K ﹤0.01% 327

Other funds holding HQL

1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
PFO
PMG Family Office Plano, Texas $109M AUM 15.87% 1-Year Est. Return
DI
Decision Investments San Diego, California $110M AUM
IFG
Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
WAP
Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return
SFS
Shaker Financial Services Arlington, Virginia $319M AUM 3.9% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

Highline Wealth Partners's HQL Position: Q2 2026 in Review

Highline Wealth Partners sold out of abrdn Life Sciences Investors (HQL) in Q2 2026, closing a stake of 175 shares — an estimated $2.85K sold.

Highline Wealth Partners first reported a position in HQL in Q3 2025 and held it in 3 quarters. The position peaked at $15.5K in Q3 2025. 12 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

  • Highline Wealth Partners reported no remaining abrdn Life Sciences Investors position as of Q2 2026 after selling out during the quarter.
  • Highline Wealth Partners sold 175 abrdn Life Sciences Investors shares in Q2 2026, an estimated $2.85K.
  • Highline Wealth Partners first reported a position in abrdn Life Sciences Investors in Q3 2025 and held it in 3 quarters.
  • Highline Wealth Partners's abrdn Life Sciences Investors position peaked at $15.5K in Q3 2025.
  • 12 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Highline Wealth Partners's 13F filing for Q2 2026, filed 15 Jul 2026.